Nanotechnology for Cancer Therapy Based on Chemotherapy

被引：254

作者：

Zhao, Chen-Yang ^{[1
]}

Cheng, Rui ^{[1
]}

Yang, Zhe ^{[1
]}

Tian, Zhong-Min ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China

来源：

MOLECULES | 2018年 / 23卷 / 04期

基金：

中国博士后科学基金;

关键词：

chemotherapy; nanoparticles; combination therapy; theranostic nanoparticles; cancer; MESOPOROUS SILICA NANOPARTICLES; DEMAND DRUG-RELEASE; EFFECTIVE PHOTOTHERMAL CHEMOTHERAPY; LOADED POLYMERIC MICELLES; NEGATIVE BREAST-CANCER; TARGETED CO-DELIVERY; CELLS IN-VITRO; PHOTODYNAMIC THERAPY; MULTIDRUG-RESISTANCE; GOLD NANOPARTICLES;

D O I：

10.3390/molecules23040826

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Chemotherapy has been widely applied in clinics. However, the therapeutic potential of chemotherapy against cancer is seriously dissatisfactory due to the nonspecific drug distribution, multidrug resistance (MDR) and the heterogeneity of cancer. Therefore, combinational therapy based on chemotherapy mediated by nanotechnology, has been the trend in clinical research at present, which can result in a remarkably increased therapeutic efficiency with few side effects to normal tissues. Moreover, to achieve the accurate pre-diagnosis and real-time monitoring for tumor, the research of nano-theranostics, which integrates diagnosis with treatment process, is a promising field in cancer treatment. In this review, the recent studies on combinational therapy based on chemotherapy will be systematically discussed. Furthermore, as a current trend in cancer treatment, advance in theranostic nanoparticles based on chemotherapy will be exemplified briefly. Finally, the present challenges and improvement tips will be presented in combination therapy and nano-theranostics.

引用

页数：29

共 242 条

[1] Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer [J].

Abbasi, Meysam ;

Lavasanifar, Afsaneh ;

Uludag, Hasan .

MEDICINAL RESEARCH REVIEWS, 2013, 33 (01) :33-53

[2]

Ajnai G., 2014, J EXP CLIN MED, V6, P172, DOI [DOI 10.1016/J.JECM.2014.10.015, 10.1016/j.jecm.2014.10.015]

[3] Construction of homogeneous antibody-drug conjugates using site-selective protein chemistry [J].

Akkapeddi, Padma ;

Azizi, Saara-Anne ;

Freedy, Allyson M. ;

Cal, Pedro M. S. D. ;

Gois, Pedro M. P. ;

Bernardes, Goncalo J. L. .

CHEMICAL SCIENCE, 2016, 7 (05) :2954-2963

[4]

[Anonymous], 2017, SMALL, DOI DOI 10.1002/SMLL.201604197

[5] A Review of Clinical Translation of Inorganic Nanoparticles [J].

Anselmo, Aaron C. ;

Mitragotri, Samir .

AAPS JOURNAL, 2015, 17 (05) :1041-1054

[6] Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors [J].

Araujo, John ;

Logothetis, Christopher .

CANCER TREATMENT REVIEWS, 2010, 36 (06) :492-500

[7] Gold nanoparticles: opportunities and challenges in nanomedicine [J].

Arvizo, Rochelle ;

Bhattacharya, Resham ;

Mukherjee, Priyabrata .

EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (06) :753-763

[8] Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles [J].

Au, Kin Man ;

Min, Yuanzeng ;

Tian, Xi ;

Zhang, Longzhen ;

Perello, Virginia ;

Caster, Joseph M. ;

Wang, Andrew Z. .

ACS NANO, 2015, 9 (09) :8976-8996

[9] DIFFUSION OF UNIVALENT IONS ACROSS LAMELLAE OF SWOLLEN PHOSPHOLIPIDS [J].

BANGHAM, AD ;

STANDISH, MM ;

WATKINS, JC .

JOURNAL OF MOLECULAR BIOLOGY, 1965, 13 (01) :238-+

[10]

Bao CC, 2014, NANOMEDICINE-UK, V9, P2353, DOI [10.2217/NNM.14.155, 10.2217/nnm.14.155]

← 1 2 3 4 5 6 7 8 9 10 →